Pharma BD Deal Intelligence
Sobi's $950M upfront bet on pozdeutinurad is paying off early: REDUCE 2 hit its primary endpoint at month 6 (75mg 69.2% vs 8.1% placebo), though the deal's full $1.5B value still hinges on REDUCE 1 data due in H2 2026.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout. Under terms, Sobi acquires Arthrosi's lead asset…
The Arthrosi acquisition gives Sobi a differentiated uricosuric asset in a gout market that remains dominated by generic xanthine oxidase inhibitors despite…
Positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad in gout (n=811). Both doses met the primary endpoint of serum urate <6 mg/dL…
Source summaries from our enrichment pipeline; follow links for originals.
All 12 sources with sentiment breakdown →
Sobi acquired Arthrosi Therapeutics for $950M upfront and up to $550M in clinical/regulatory/sales milestones (total up to $1.5B); the acquisition closed in February 2026. The deal added pozdeutinurad (AR882), a once-daily oral URAT1 inhibitor for progressive and tophaceous gout, studied in two pivotal global Phase 3 trials, REDUCE 1 and REDUCE 2. On 21 May 2026, Sobi reported positive topline results from REDUCE 2 (n=811): both doses met the primary endpoint of serum urate <6 mg/dL at month 6 (75 mg 69.2% vs 8.1% placebo, p<0.0001; 50 mg 56.6% vs 8.1%, p<0.0001), with a safety profile consistent with prior studies. REDUCE 1 is fully enrolled with data expected in H2 2026, and detailed REDUCE 2 results are slated for a scientific congress in Q4 2026. The positive first pivotal readout supports the original deal thesis of a differentiated, next-generation uricosuric for patients inadequately controlled on first-line urate-lowering therapy.
9.2M US cases/yr · $11.2B Global gout therapeutics market (2030 projection) · 50% Allopurinol patients failing to reach target serum urate
Gout is the most common inflammatory arthritis, affecting approximately 9.2 million US adults per NHANES/CDC data. It results from chronic hyperuricemia leading to monosodium urate crystal deposition in joints and soft tissues, causing acute painful flares and, if untreated, progressive joint destruction, tophi formation, and renal complications. Progressive and tophaceous gout represents the more severe spectrum: patients with visible tophi, frequent flares (>=2/year despite therapy), radiographic joint damage, or chronic arthropathy. Standard urate-lowering therapy (ULT) uses xanthine oxidase inhibitors allopurinol and febuxostat. Approximately 50% of patients on allopurinol fail to achieve target serum urate (<6 mg/dL), driven by inadequate dosing, adherence, and tolerability. Pegloticase (Krystexxa, Horizon/Amgen) serves refractory gout via uricase mechanism but requires IV infusion and immunogenicity management. Uricosurics (URAT1 inhibitors) - probenecid, lesinurad (withdrawn), and now pozdeutinurad - offer an alternative mechanism by enhancing renal urate excretion. Pozdeutinurad's differentiation: once-daily oral, selective URAT1 inhibition, without the hepatic/cardiovascular signals that troubled earlier uricosurics.
Gout therapeutic landscape is structurally bifurcated between urate-lowering maintenance therapy and acute flare management. Xanthine oxidase inhibitors dominate chronic ULT: allopurinol (generic, $500M+ US market) and febuxostat/Uloric (Takeda, now generic following patent expiry) serve first-line despite cardiovascular label concerns on febuxostat. Refractory patients rely on pegloticase/Krystexxa (Amgen/Horizon, $1B+ run rate) via recombinant uricase enzymatic urate clearance, typically paired with methotrexate immunomodulation to manage immunogenicity. Uricosurics/URAT1 inhibitors include probenecid (legacy generic, limited use), benzbromarone (not US approved due to hepatotoxicity signals), and dotinurad (approved Japan, Fuji Yakuhin). Lesinurad/Zurampic from Ironwood was withdrawn US 2019. Selecta Biosciences's SEL-212 (pegadricase plus ImmTOR tolerogenic nanoparticle, Sobi licensed rights in 2020) was Sobi's prior gout platform and failed Phase 3 in 2023, necessitating pipeline replacement. Pozdeutinurad/AR882 represents next-generation URAT1 inhibition with two fully-enrolled global Phase 3 trials (REDUCE 1 and REDUCE 2) and pivotal data expected 2026. Competing URAT1 and combination programs include Crystalys Therapeutics' CRY-9701 (Phase 1/2), LG Chem's tigulixostat (Phase 3, xanthine oxidase inhibitor), and Atom Bioscience's AR882 derivatives. Sobi's acquisition positions pozdeutinurad as its lead rheumatology asset post-Selecta pivot.
Sobi reported positive topline results from the pivotal Phase 3 REDUCE 2 study of pozdeutinurad (AR882) in gout (n=811). Both doses met the primary endpoint of serum urate <6 mg/dL at month 6 (75 mg 69.2% vs 8.1% placebo, p<0.0001; 50 mg 56.6% vs 8.1%, p<0.0001); safety consistent with prior studies. First pivotal readout post-acquisition; REDUCE 1 data expected H2 2026.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Swedish Orphan Biovitrum AB / Arthrosi Therapeutics, Inc. (this deal) | 2025 | $1.5B | — |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Swedish Orphan Biovitrum AB / AstraZeneca PLC (Synagis US rights) | 2018 | $2.3B | 80 |
| Swedish Orphan Biovitrum AB / Innate Pharma SA | 2026 | $580M | 68 |
| Swedish Orphan Biovitrum AB / CTI BioPharma Corp. | 2023 | $1.7B | 60 |
| Swedish Orphan Biovitrum AB / Apellis Pharmaceuticals, Inc. | 2020 | $1.0B | — |
| Horizon Pharma plc / Crealta Holdings LLC | 2015 | $510M | 87 |
← Browse all deals · How we score deals
More: 2025 deals · Swedish Orphan Biovitrum AB deals · Nephrology deals